Name in SEC filings: Eikon Therapeutics, Inc.
| Program | Event | Stage | Stated timing | Filing |
|---|---|---|---|---|
| EIK1001 | /data readout | Stage not stated | in October 2026 | 10-Q · |
| EIK1003 | Topline/data readout | Stage not stated | in October 2026 | 10-Q · |
| EIK1003 | Topline/data readout | Stage not stated | in October 2026 | 10-Q · |
| EIK1005 | Topline/data readout | Stage not stated | in October 2026 | 10-Q · |
| EIK1003 | Topline/data readout | Stage not stated | ESMO Congress 2026 in October | 10-Q · |
| EIK1004 | Topline/data readout | Stage not stated | ESMO Congress 2026 in October | 10-Q · |
| EIK1006 | submission | — | by the end of 2026 | 10-Q · |
Source: ORION, orionbiotechai.com/company/EIKN, data as of Oct 16, 2026
https://www.orionbiotechai.com/company/EIKN
EIK1001 · Topline/data readout · in October 2026
SEC sources last checked .
○ Quote matched to filing (not yet reviewed by founder) · ✓ Checked by founder.
Topline/data readoutin October 2026
Stage: Not stated
Public float: Unknown (no public float found in SEC filings).
We expect to present updated data from TeLuRide-005 at the 2026 European Society of Medical Oncology, or ESMO, Congress in October 2026.
SEC timing context:
We completed enrollment in TeLuRide-005 in the first quarter of 2026.
10-Q · Filed · Last checked
Alert me · Calendar: same stage and window-end month (2026-10)
Topline/data readoutin October 2026
Stage: Not stated
Public float: Unknown (no public float found in SEC filings).
We plan to present updated data from Cohort 1A at the ESMO Congress 2026 in October 2026.
SEC timing context:
We are evaluating EIK1003 in Cohort 1A as a monotherapy for the treatment of patients with ovarian, breast, prostate, and pancreatic cancers.
10-Q · Filed · Last checked
Alert me · Calendar: same stage and window-end month (2026-10)
Topline/data readoutin October 2026
Stage: Not stated
Public float: Unknown (no public float found in SEC filings).
We plan to present the updated clinical data from Cohort 1C at the ESMO Congress 2026 in October 2026.
SEC timing context:
Cohort 1C is evaluating EIK1003 in combination with paclitaxel for the treatment of patients with platinum-resistant ovarian cancer or patients with HER2-negative breast cancer that have failed hormonal therapy if ER+ or chemotherapy if ER negative.
10-Q · Filed · Last checked
Alert me · Calendar: same stage and window-end month (2026-10)
Topline/data readoutin October 2026
Stage: Not stated
Public float: Unknown (no public float found in SEC filings).
We plan to present initial clinical data from this trial at the ESMO Congress 2026 in October 2026.
SEC timing context:
We are currently evaluating EIK1005 in a Phase 1/2 trial as monotherapy and in 25 combination with pembrolizumab in participants with advanced solid tumors.
10-Q · Filed · Last checked
Alert me · Calendar: same stage and window-end month (2026-10)
Topline/data readoutESMO Congress 2026 in October
Stage: Not stated
Public float: Unknown (no public float found in SEC filings).
We plan to present initial clinical data from Cohort 1B at the ESMO Congress 2026 in October.
SEC timing context:
Cohort 1B is evaluating EIK1003 in combination with abiraterone and prednisone for the treatment of patients with advanced prostate cancer.
10-Q · Filed · Last checked
Topline/data readoutESMO Congress 2026 in October
Stage: Not stated
Public float: Unknown (no public float found in SEC filings).
We plan to present the first clinical data from this trial at the ESMO Congress 2026 in October.
SEC timing context:
We are also conducting a Phase 1/2 trial evaluating the safety and efficacy of EIK1004, our selective PARP1 inhibitor designed to penetrate the central nervous system, for the treatment of patients with ovarian, breast, prostate, and pancreatic cancers.
10-Q · Filed · Last checked
NDA/BLA submissionby the end of 2026
Stage: —
Public float: Unknown (no public float found in SEC filings).
We expect to submit an investigational new drug application, or IND, for EIK1006 by the end of 2026.
10-Q · Filed · Last checked
Company periods and sentences are quoted as written. A matching disclosure uses the SEC filing date for the same program and event type. As of .
| Program / event | Stated period and SEC wording | Disclosure in stated period |
|---|---|---|
| EIK1001Clinical results | in October 2026“We expect to present updated data from TeLuRide-005 at the 2026 European Society of Medical Oncology, or ESMO, Congress in October 2026.” Filed · 10-Q | Still within period As of Oct 19, 2026 |
| EIK1003Clinical results | in October 2026“We plan to present updated data from Cohort 1A at the ESMO Congress 2026 in October 2026.” Filed · 10-Q | Still within period As of Oct 19, 2026 |
| EIK1003Clinical results | ESMO Congress 2026 in October“We plan to present initial clinical data from Cohort 1B at the ESMO Congress 2026 in October.” Filed · 10-Q | Not compared ORION has no confirmed start and end dates for this wording, so it is not compared with filings. |
| EIK1003Clinical results | in October 2026“We plan to present the updated clinical data from Cohort 1C at the ESMO Congress 2026 in October 2026.” Filed · 10-Q | Still within period As of Oct 19, 2026 |
| EIK1004Clinical results | ESMO Congress 2026 in October“We plan to present the first clinical data from this trial at the ESMO Congress 2026 in October.” Filed · 10-Q | Not compared ORION has no confirmed start and end dates for this wording, so it is not compared with filings. |
| EIK1005Clinical results | in October 2026“We plan to present initial clinical data from this trial at the ESMO Congress 2026 in October 2026.” Filed · 10-Q | Still within period As of Oct 19, 2026 |
| EIK1006Submission | by the end of 2026“We expect to submit an investigational new drug application, or IND, for EIK1006 by the end of 2026.” Filed · 10-Q | Not compared ORION has no confirmed start and end dates for this wording, so it is not compared with filings. |
“Not compared” means ORION has not matched this wording against a complete set of SEC filings for its period. It says nothing either way about whether a matching filing exists. Wording without exact dates is not given calendar dates.
Suggest an SEC timing statement to add for EIKN. You can include the original filing link in your note. The founder reads each request by hand.
Or email ORION.
See EIKN in the calendar · Review labels and methodology